Home  /  Resource Library  /  Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged >60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged >60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

ASH 2023